

FDA approves Sun Pharma's inflammatory drug

20 August 2015 | News | By BioSpectrum Bureau

FDA approves Sun Pharma's inflammatory drug



Singapore: India's Sun Pharmaceutical has received US Food and Drug Administration (FDA) for supplemental new drug application (sNDA) for Ximino (Minocycline HCl) extended-release capsules 45 mg, 90 mg and 135 mg.

Ximino extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. It expects Ximino extended-release capsules to be available for patients during the fourth quarter of 2015.

Ximino extended-release capsules consist of extended release formulation of Minocycline HCl capsules 45 mg, 90 mg and 135 mg and are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of

age and older.